Aerie is one of a growing number of pharmaceutical companies that have used novel methods to develop drugs for cancer, diabetes and chronic pain.
Aerie’s research has made it a favorite among drugmakers for its ability to quickly develop new and promising compounds.
The company says it has developed new drugs to treat multiple conditions and multiple types of cancer.
Aery, which is based in Irvine, California, has a research arm focused on the treatment of cancer and other diseases.
“It’s a very unique position,” Aery’s chief executive, Mark Stoll, told CNBC’s “Squawk Box.”
“We have been looking for the next big thing in drugs and it’s just really hard to find a company that does it as well as Aery.”
Aery has developed drugs for the treatment, prevention and control of certain types of arthritis, pain and obesity.
The team also developed drugs to control inflammatory and allergic conditions and asthma.
Ayera is a startup focused on treating Parkinson’s disease, multiple sclerosis, multiple organ system disorders, neurodegenerative diseases and inflammatory diseases.
Ayers is also focusing on cancer and inflammatory disorders.
It says it develops and tests a range of cancer-fighting and anti-inflammatory drugs, including a vaccine against pancreatic cancer.
The firm also offers anti-bacterial and anti-(tumor) immune systems, skin cancer screening and cardiovascular disease treatments.
Aayrea is based on Aery.
The startup has focused on developing and testing anti-cancer and antiplatelet drugs.
It also develops new treatments for diabetes, obesity and metabolic syndrome.
“We are looking at a broad range of diseases,” Stoll said.
“Some of our targets are cancer, some are inflammatory and some are diabetes.”
Aayra has a wide range of drugs for multiple conditions, including inflammatory bowel diseases, cardiovascular diseases and diabetes.
“What we’re really looking for is an approach to cancer and to inflammatory diseases that can help people live longer, stronger and healthier lives,” Stolly said.
The Aayresis also develops novel drugs for Parkinson’s and Parkinson’s patients.
“There are lots of potential uses for the Aayraya platform, and we believe we have the potential to take this forward,” Stoller said.
Ayras is based out of Irvine, Calif., with offices in Santa Barbara, Calif.
Stoll was a key member of the team that developed a gene therapy for Parkinson disease.
“I was just as involved in the development of the treatment as the team,” Stell said.
Stoller has also served as an advisor to Ayrasea and is a founding member of its board.
Aalya is an Indian company that developed an anti-oxidant therapy that has helped patients with cardiovascular diseases.
It is based at the University of California, Irvine.
The San Francisco-based company has a long history of clinical development and has more than $400 million in funding in its pipeline.
“The most exciting thing about us is that we’re doing things that aren’t just focused on just the pharmaceutical industry, but also on other areas that can make a big difference in our lives,” said Aalyas CEO and founder, Amit Thakur.
Aya is a pharmaceutical research company based in the United Kingdom.
The group has a number of clinical trials in its portfolio, including some in humans and mice.
The business is also working on a treatment for the severe autoimmune disorder lupus.
“As we go forward, it’s really important to have a wide variety of potential outcomes,” Thakar said.
Thakumas also has a focus on cancer research.
“If we can provide an efficient and effective therapy to people who have this disease, we can also have a long-term impact on the lives of people,” Thamayar said, adding that he is looking to help other patients with this disease.